ClinicalTrials.gg
CompletedNCT01986660Updated Jan 27, 2014

Open-Label, Maximum-Dose Pharmacokinetic Study of 7.5% Ibuprofen Cream (SST-0225) in Healthy Adults

A Phase 1 interventional study of Ibuprofen Cream (SST-0225) in Healthy, sponsored by Strategic Science & Technologies, LLC. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-01-27.

Sponsored by Strategic Science & Technologies, LLC · Phase 1 and Interventional

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
14
Allocation
Not applicable
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The purpose of this study is to evaluate how Ibuprofen Cream (SST-0225) is absorbed and eliminated by the body under defined maximum dosing conditions and to evaluate the safety under these conditions.

02

Conditions studied

  • Healthy

Keywords

  • Pharmacokinetic Study
03

In context

Lead sponsor

Strategic Science & Technologies, LLC is the lead sponsor of 9 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed consent form
  • Men, women, 18 to 55 years
  • Females must not be pregnant or plan to become pregnant
  • 18 to 30 kg/m2
  • Past or non-smoker
  • High probability of compliance with completion of study
  • Healthy as determined by investigator based on medical history, physical exam, clinical laboratory tests, vital sign measurements, ECGs

Exclusion criteria

Exclusion Criteria:

  • Presence or history of disorder that could interfere with completion of study
  • Unstable medical condition
  • Surgical or medical condition that may interfere with absorption, distribution, metabolism or excretion of test drug
  • Positive Hep B, Hep C and/or test
  • Positive urine drug screen
  • Any history of skin disorders, including psoriasis, eczema, tattoos, significant scarring, healing wounds, skin lesions on knees or elbows
  • Significant disease
  • Any deviation from normal limits in physical exam, vital sign measurements, 12 lead , clinical laboratory test
  • History of drug abuse with 1 year
  • History of alcoholism with 1 year
  • Use of prescription medications or ibuprofen within 30 days of Day 1, use of OTC drugs, herbal supplements and vitamins within 14 days of Day 1.
  • Use of drug within 30 day of Day 1
  • Acute disease state within 7 days of Day 1
  • Consumption of grapefruit or grapefruit containing products within 72 hours of Day 1
  • Tobacco use/caffeine use within 48 hours of Day 1
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
14 participants (actual)

Study arms

  • Experimental
    Ibuprofen Cream (SST-0225)

    Drug: Ibuprofen Cream (SST-0225)

06

What researchers measure

Primary outcomes

  1. Cmax, Tmax, Trough Concentrations Days 2 to 8, AUC 0-24, Steady State, T1/2

    Time frame: 9 days

Secondary outcomes

  1. Clinical laboratory change from baseline

    Time frame: 14 days

  2. Modified Berger Bowman Skin Assessment

    Time frame: 14 days

  3. Vital Signs

    Time frame: 14 days

  4. Adverse Events

    Time frame: 14 days

07

Study locations

1 site
  • SST Investigational Site
    New York, New York, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2013, a primary completion of Oct 2013 and a completion of Oct 2013. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 29, 2013
First posted
Nov 18, 2013
Start
Oct 2013
Primary completionActual
Oct 2013
CompletionActual
Oct 2013
Last update
Jan 27, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 27, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01986660
Lead sponsor
Strategic Science & Technologies, LLC
Responsible party
Sponsor
First posted
Nov 18, 2013
Start date
Oct 2013
Primary completion
Oct 2013
Completion
Oct 2013
Last update
Jan 27, 2014
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ibuprofen

Start the discussion